Obesity
-
Randomized Controlled Trial
A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II).
To examine the effects of naltrexone/bupropion (NB) combination therapy on weight and weight-related risk factors in overweight and obese participants. ⋯ NB represents a novel pharmacological approach to the treatment of obesity, and may become a valuable new therapeutic option.